Biofrontera Accounts Payable from 2010 to 2024
| BFRI Stock | USD 0.99 0.03 2.94% |
Accounts Payable | First Reported 2010-12-31 | Previous Quarter 8.9 M | Current Value 9.4 M | Quarterly Volatility 2.9 M |
Check Biofrontera financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biofrontera's main balance sheet or income statement drivers, such as Tax Provision of 33 K, Interest Income of 90.6 K or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 0.12, Dividend Yield of 0.0 or PTB Ratio of 0.85. Biofrontera financial statements analysis is a perfect complement when working with Biofrontera Valuation or Volatility modules.
Biofrontera | Accounts Payable |
Latest Biofrontera's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Biofrontera over the last few years. An accounting item on the balance sheet that represents Biofrontera obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Biofrontera are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Biofrontera's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biofrontera's overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Biofrontera Accounts Payable Regression Statistics
| Arithmetic Mean | 1,994,487 | |
| Geometric Mean | 1,196,533 | |
| Coefficient Of Variation | 145.68 | |
| Mean Deviation | 1,902,444 | |
| Median | 821,000 | |
| Standard Deviation | 2,905,572 | |
| Sample Variance | 8.4T | |
| Range | 8.7M | |
| R-Value | 0.62 | |
| Mean Square Error | 5.6T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | 399,765 | |
| Total Sum of Squares | 118.2T |
Biofrontera Accounts Payable History
About Biofrontera Financial Statements
Investors use fundamental indicators, such as Biofrontera's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Biofrontera's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 8.9 M | 9.4 M |
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out the analysis of Biofrontera Correlation against competitors. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.16 | Revenue Per Share 11.573 | Quarterly Revenue Growth 0.34 | Return On Assets (0.40) | Return On Equity (1.49) |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.